Would you offer immunotherapy after chemoradiotherapy for Stage III lung cancer given results of PACIFIC Trial?
If so how would you select patients (ie. PS, histology, PD-L1 expression level)?
Answer from: Medical Oncologist at Academic Institution
In light of the comments by Professor Vansteenkinste comparing the ESMO 2017 plenary session incorporating the PACIFIC study results as a “tsunami” in the footsteps of last year’s ESMO lung cancer “earthquake” presentations, an appropriate title to this question might b...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Upon FDA approval I will offer durvalumab for my definitively chemoradiation treated stage III patients who have acceptable lung volume radiation dosing. The trial population was "real world" with no restrictions on types of chemotherapy or planned radiation cycles provided the radiation dose was 5...
Comments
Radiation Oncologist at Turville Bay MRI & Radiation Oncology Center
Overall survival now available NEJM online Sept. 2...
Overall survival now available NEJM online Sept. 2...